Page last updated: 2024-11-07

4-androstene-3,17-diol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-androstene-3,17-diol: RN given refers to (3alpha,17beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID136297
CHEMBL ID195836
CHEBI ID34386
SCHEMBL ID183700
MeSH IDM0075968

Synonyms (42)

Synonym
unii-g10eha9i0d
delta4-androstene-3beta,17beta-diol
3beta,17beta-dihydroxy-4-androstene
g10eha9i0d ,
nsc 12458
androst-4-ene-3,17-diol, (3beta,17beta)-
androst-4-ene-3beta,17beta-diol
4-androstenediol
3.beta.,17.beta.-dihydroxy-4-androstene
1156-92-9
nsc-12458
androst-4-ene-3.beta.,17.beta.-diol
.delta.4-androstene-3.beta.,17.beta.-diol
nsc12458
androst-4-ene-3, (3.beta.,17.beta.)-
DB01526
chebi:34386 ,
CHEMBL195836 ,
LMST02020105
4-androstene-3,17-diol
androst-4-ene-3,17-diol
(3s,8r,9s,10r,13s,14s,17s)-10,13-dimethyl-2,3,6,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-3,17-diol
bdbm50410526
SCHEMBL183700
4-androstene-3.beta.o,17.beta.-diol
androst-4-ene-1,1 diol
4-andendiol
testosterone impurity d [ep impurity]
DTXSID5036505
4-androsten-3beta,17beta-diol
4-androstene-3beta,17beta-diol
(3b,17b)-androst-4-ene-3,17-diol
androst-4-en-3b,17b-diol
d4-androstene-3b,17b-diol
3b,17b-dihydroxy-4-androstene
androst-4-ene-3b,17b-diol
4-androstene-3b,17b-diol
androst-4-ene-3beta,17beta-diol; testosterone imp. d (ep); delta4-androstenediol; testosterone impurity d
androst-4-ene-3beta,17beta-diol (?4-androstenediol)
Q3324829
androst-4-ene-3beta,17beta-diol (delta4-androstenediol)
PD008806
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
androgenA sex hormone that stimulates or controls the development and maintenance of masculine characteristics in vertebrates by binding to androgen receptors.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
3-hydroxy steroidAny hydroxy steroid carrying a hydroxy group at position 3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Androgen receptor network in prostate cancer434
Steroid biosynthesis04

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Androgen receptorRattus norvegicus (Norway rat)IC50 (µMol)0.63100.00101.979414.1600AID255211
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sex hormone-binding globulinHomo sapiens (human)Kd0.00100.00020.34964.7863AID318680
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
androgen bindingSex hormone-binding globulinHomo sapiens (human)
protein bindingSex hormone-binding globulinHomo sapiens (human)
steroid bindingSex hormone-binding globulinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
extracellular regionSex hormone-binding globulinHomo sapiens (human)
extracellular exosomeSex hormone-binding globulinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID255211Inhibitory concentration against recombinant rat androgen receptor expressed in Escherichia coli using [3H]methyltrienolone (R 1881)2005Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18
Impact of induced fit on ligand binding to the androgen receptor: a multidimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals.
AID672711Inhibition of aromatase in human placental microsomes using [1beta-3H]androstenedione as substrate at 2 uM after 15 mins by liquid scintillation counting2012Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8
New structure-activity relationships of A- and D-ring modified steroidal aromatase inhibitors: design, synthesis, and biochemical evaluation.
AID318680Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
An updated steroid benchmark set and its application in the discovery of novel nanomolar ligands of sex hormone-binding globulin.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (30.77)18.7374
1990's2 (15.38)18.2507
2000's4 (30.77)29.6817
2010's3 (23.08)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.86

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.86 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.86)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (7.69%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]